ID | 114800 |
Author |
Bando, Hiroshi
Tokushima University|Japan low carbohydrate diet promotion association
KAKEN Search Researchers
|
Keywords | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Canagliflozin Cardio-Vascular Assessment Study (CANVAS)
Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE)
Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58
The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) Study
|
Content Type |
Journal Article
|
Description | Diabetes has been a major medical and health problem worldwide. Adequate glycemic control has shown a clinically beneficial effect for long-term prognosis, with recent anti-diabetic agents. There are some mega studies concerning Sodium-glucose cotransporter 2 (SGLT2) inhibitors. They are i) Canagliflozin cardioVascular Assessment Study (CANVAS), ii) Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), iii) Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58, iv) Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study. Current topics of SGLT2 inhibitors for cardiovascular and renal points of view were described.
|
Journal Title |
Diabetes Research : Open Access
|
Publisher | Asploro
|
Volume | 2
|
Issue | S1
|
Start Page | 9
|
End Page | 13
|
Published Date | 2020-01-30
|
Rights | © 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
|